ARS Pharmaceuticals, Inc. (SPRY) EBIT

Annual EBIT:

-$3.08M+$64.44M(+95.43%)
December 31, 2024

Summary

  • As of today, SPRY annual earnings before interest & taxes is -$3.08 million, with the most recent change of +$64.44 million (+95.43%) on December 31, 2024.
  • During the last 3 years, SPRY annual EBIT has risen by +$16.37 million (+84.15%).
  • SPRY annual EBIT is now at all-time high.

Performance

SPRY EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYincome statement metrics

Quarterly EBIT:

-$53.19M-$5.58M(-11.72%)
September 30, 2025

Summary

  • As of today, SPRY quarterly earnings before interest & taxes is -$53.19 million, with the most recent change of -$5.58 million (-11.72%) on September 30, 2025.
  • Over the past year, SPRY quarterly EBIT has dropped by -$31.44 million (-144.58%).
  • SPRY quarterly EBIT is now -212.70% below its all-time high of $47.20 million, reached on December 31, 2024.

Performance

SPRY Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYincome statement metrics

TTM EBIT:

-$90.79M-$31.44M(-52.99%)
September 30, 2025

Summary

  • As of today, SPRY TTM earnings before interest & taxes is -$90.79 million, with the most recent change of -$31.44 million (-52.99%) on September 30, 2025.
  • Over the past year, SPRY TTM EBIT has dropped by -$30.28 million (-50.04%).
  • SPRY TTM EBIT is now -2844.73% below its all-time high of -$3.08 million, reached on December 31, 2024.

Performance

SPRY TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

SPRY EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+95.4%-144.6%-50.0%
3Y3 Years+84.2%-702.3%-108.3%
5Y5 Years+87.2%-306.0%-266.0%

SPRY EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+95.4%-212.7%at low-2844.7%at low
5Y5-Yearat high+95.4%-212.7%at low-2844.7%at low
All-TimeAll-Timeat high+95.4%-212.7%at low-2844.7%at low

SPRY EBIT History

DateAnnualQuarterlyTTM
Sep 2025
-
-$53.19M(-11.7%)
-$90.79M(-53.0%)
Jun 2025
-
-$47.61M(-28.1%)
-$59.34M(-119.2%)
Mar 2025
-
-$37.18M(-178.8%)
-$27.07M(-778.0%)
Dec 2024
-$3.08M(+95.4%)
$47.20M(+317.0%)
-$3.08M(+94.9%)
Sep 2024
-
-$21.75M(-41.8%)
-$60.51M(-6.6%)
Jun 2024
-
-$15.34M(-16.3%)
-$56.74M(+8.5%)
Mar 2024
-
-$13.19M(-29.0%)
-$62.00M(+8.2%)
Dec 2023
-$67.52M(-90.1%)
-$10.23M(+43.1%)
-$67.52M(-17.8%)
Sep 2023
-
-$17.98M(+12.7%)
-$57.29M(-24.7%)
Jun 2023
-
-$20.60M(-10.1%)
-$45.95M(-45.0%)
Mar 2023
-
-$18.71M(-182.2%)
-$31.69M(+27.3%)
Dec 2022
-$35.52M
-
-
DateAnnualQuarterlyTTM
Sep 2022
-
-$6.63M(-4.5%)
-$43.58M(+26.9%)
Jun 2022
-
-$6.34M(+10.6%)
-$59.63M(+23.4%)
Mar 2022
-
-$7.10M(+69.8%)
-$77.80M(+13.2%)
Dec 2021
-$19.45M(+40.9%)
-
-
Dec 2021
-
-$23.51M(-3.6%)
-$89.58M(-13.1%)
Sep 2021
-
-$22.68M(+7.5%)
-$79.18M(-40.1%)
Jun 2021
-
-$24.51M(-29.8%)
-$56.50M(-46.9%)
Mar 2021
-
-$18.89M(-44.1%)
-$38.45M(-55.0%)
Dec 2020
-$32.92M(-36.8%)
-$13.10M(-102.7%)
-$24.81M(-33.1%)
Jun 2020
-
-$6.46M(-23.3%)
-$18.64M(-53.1%)
Mar 2020
-
-$5.24M(+24.4%)
-$12.17M(-75.6%)
Dec 2019
-$24.07M(-31.4%)
-$6.93M
-$6.93M
Dec 2018
-$18.32M
-
-

FAQ

  • What is ARS Pharmaceuticals, Inc. annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. annual EBIT year-on-year change?
  • What is ARS Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
  • What is ARS Pharmaceuticals, Inc. TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. TTM EBIT year-on-year change?

What is ARS Pharmaceuticals, Inc. annual earnings before interest & taxes?

The current annual EBIT of SPRY is -$3.08M

What is the all-time high annual EBIT for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$3.08M

What is ARS Pharmaceuticals, Inc. annual EBIT year-on-year change?

Over the past year, SPRY annual earnings before interest & taxes has changed by +$64.44M (+95.43%)

What is ARS Pharmaceuticals, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of SPRY is -$53.19M

What is the all-time high quarterly EBIT for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is $47.20M

What is ARS Pharmaceuticals, Inc. quarterly EBIT year-on-year change?

Over the past year, SPRY quarterly earnings before interest & taxes has changed by -$31.44M (-144.58%)

What is ARS Pharmaceuticals, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of SPRY is -$90.79M

What is the all-time high TTM EBIT for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is -$3.08M

What is ARS Pharmaceuticals, Inc. TTM EBIT year-on-year change?

Over the past year, SPRY TTM earnings before interest & taxes has changed by -$30.28M (-50.04%)
On this page